Halotestin
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Halotestin is a narrow competition-day androgen: acute aggression, neural drive, and weight-class water handling, not mass gain or general recomposition.
C17-alpha-alkylated oral with high hepatotoxicity potential — do not run longer than 4 weeks total or exceed 20 mg/day without LFT monitoring; cycles beyond 4 weeks risk severe cholestatic jaundice requiring months of recovery.
Halotestin is a narrow competition-day androgen: acute aggression, neural drive, and weight-class water handling, not mass gain or general recomposition.
Severe HDL crash (single digits have been reported at 20-30 mg/day), cholestatic liver injury when dose or duration drifts upward, social spillover from CNS aggression, blood-pressure elevation, and complete HPG suppression.
Expensive at roughly $3-8 per 10 mg tablet with a high counterfeiting rate; a 4-week 20 mg/day run can cost about $84-224 before testosterone base, testing, labs, and ancillaries. The price premium only makes sense for a defined competition event.
Highly effective for its specific narrow purpose: acute CNS drive and aggression on competition day. Community consensus is clear that it delivers zero mass gains and should not be expected to — users pursuing it for anabolic effect will be disappointed.
Do not run halotestin as an oral-only cycle — complete HPG suppression without a testosterone base leaves you on zero sex hormones; always pair with testosterone propionate 100-200 mg/week.
Intro
Halotestin (fluoxymesterone) is a synthetic 17-alpha-alkylated oral androgen derived from testosterone with two structural modifications: a 9-alpha-fluoro group and an 11-beta-hydroxy group.
The 17-alpha-methyl group provides approximately 80% oral bioavailability by blocking first-pass hepatic metabolism. It was FDA-approved in the 1950s for male hypogonadism, delayed puberty, and palliative treatment of inoperable breast cancer in women — uses that have largely been superseded by modern alternatives.
The compound presents a fundamental pharmacological paradox: its androgen receptor binding affinity is approximately 1900% that of testosterone (Kd ~0.3 nM), yet its clinical anabolic effect is paradoxically weak. This dissociation is explained by two in-vivo inactivation mechanisms. In peripheral tissues, the 11-beta-hydroxy group is oxidized to 11-keto-fluoxymesterone, which has dramatically reduced AR affinity. Simultaneously, the 9-alpha-fluoro group promotes rapid A-ring reduction to less-active metabolites specifically in muscle tissue. The net result is a compound that is strongly androgenic in CNS and androgenic tissues, but minimally anabolic in skeletal muscle — distinguishing it from oxymetholone and oxandrolone, which retain their anabolic activity in vivo.
The unique mechanism that defines halotestin's athletic application is its inhibition of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) with IC50 approximately 60-100 nM in human renal microsomes. By blocking the conversion of cortisol to cortisone in mineralocorticoid-sensitive tissues, halotestin allows cortisol to accumulate at mineralocorticoid receptors — producing apparent mineralocorticoid excess (sodium retention, potassium loss, blood pressure elevation) while indirectly suppressing aldosterone feedback. This mechanism provides the weight-cut benefit that has attracted combat sports athletes.
Athletic adoption has remained narrow and competition-specific. Powerlifters use it for peak-week CNS priming; combat sports athletes use it pre-fight for aggression and weight management; bodybuilders occasionally use it as a final contest-prep hardener. Community consensus has firmly repositioned halotestin from an anabolic agent into a neurological compound — a CNS stimulant in AAS form. Anyone expecting it to produce mass gains will be disappointed. The compound was WADA-banned since the 1976 Montreal Olympics; its 9-alpha-fluoro GC-MS signature is structurally unique and cannot be masked, making it extremely dangerous for any tested athlete.
Observed Effects
Primary intended effects
The primary documented benefit is acute CNS enhancement: aggression, drive, and neural recruitment for maximal-effort performance. This effect appears within hours of dosing (distinct from anabolic effects that develop over weeks), peaks at approximately 90 minutes post-dose, and lasts 4-6 hours. Powerlifters report substantial meet-day strength increases — one documented log showed a 55 kg total increase on competition day (bench 165 to 185 kg, squat 230 to 250, deadlift 270 to 295) on a protocol of 20 mg/day for 4 weeks with testosterone propionate base.
Training intensity and mental drive are consistently reported even at lower doses. A 10 mg/day contest prep log described powering through two-a-day workouts without the usual afternoon mental fatigue — a training quality benefit distinct from the acute competition-day effect.
A subtle hardening effect during caloric deficits appears by week 2 at doses 10-20 mg/day, attributed to partial glucocorticoid receptor agonism providing mild anti-catabolic protection.
Weight management
Via the 11-beta-HSD2 inhibition mechanism, users report approximately 2-3 lbs of water loss in the week before weigh-in compared to baseline. This is the pharmacological basis for combat sports weight-class management — effective without the dehydration risk of diuretics.
Fertility paradox (clinical context)
A review of 17 clinical trials for male subfertility found that fertility parameters improved at doses of 10-30 mg/day for 3-12 months, despite androgen-driven suppression of LH and FSH. The proposed mechanism is direct Sertoli cell AR agonism and anti-glucocorticoid action providing a direct spermatogenic stimulus. This clinical use case is paradoxical and distinct from the athletic application.
What halotestin does NOT do
Zero mass gain at standard athletic doses. Community consensus is categorical: this is not a bulking compound, not a recomposition tool, and not suitable for any goal requiring sustained anabolic activity. Users who pursue halotestin expecting the anabolic returns of Dianabol or Anadrol will get nothing but side effects.
Field Reports
What works
The competition-day CNS effect is the most consistently documented benefit. Powerlifters describe elevated aggression and neural recruitment that allows exceeding training maxes under competition conditions. One user who stopped halotestin a full week before their meet due to unmanageable aggression still PR'd every lift on meet day, suggesting the noradrenergic upregulation outlasts drug clearance — a practical observation that raises the option of stopping 1-2 weeks early to reduce total liver exposure while retaining most competition benefit.
What does not work
Mass gain at any athletic dose: zero, categorically. Users pursuing halotestin for anabolic returns comparable to Dianabol or Anadrol are uniformly disappointed. The aggression cannot be directed or gym-limited — it is reactive and spills into daily life. Multiple users describe the same pattern: useful in a controlled competition environment, destabilizing outside it.
Common mistakes
Running without a testosterone base (oral-only) is the most common error, resulting in complete sex hormone deprivation within 2 weeks. Extending beyond 4 weeks is the second most common error — a 6-week run at 15 mg/day produced 8x ULN liver enzymes and took 3 months with UDCA support to resolve. Purchasing without lab testing and receiving anavar or winstrol sold as halotestin is widespread.
Protocol refinements from experienced users
Split dosing (10 mg twice daily) for stable CNS support during multi-week prep; single pre-event dosing for acute competition-day peak. TUDCA 500 mg/day throughout the cycle; NAC 600 mg/day post-cycle for liver recovery. Telmisartan 20-40 mg/day if BP exceeds 140/90 during the run.
Community Consensus
Halotestin consensus is unusually clear because the niche is so narrow. Experienced users treat it as a neurological competition tool, not an anabolic builder: powerlifting meet-day drive, striking-sport aggression, weight-class water management, and occasional final-stage contest hardening. The strongest favorable posture is bullish but bounded — it can move a maximal-effort event when timing, dose, sourcing, and monitoring are controlled, but it is a poor choice for almost every ordinary physique or strength goal.
The same community consensus is harsh about misuse. Halotestin-only cycles are treated as a beginner error because suppression arrives quickly and the compound provides no estrogen support. Extending past 4 weeks, stacking multiple harsh orals casually, or using it during a volatile life period are viewed as avoidable harm. The aggression is not neatly gym-contained; reports describe reactive, hair-trigger behavior that damages relationships, work, and day-to-day judgment.
Sourcing shapes the community read almost as much as pharmacology. Raw fluoxymesterone is far more expensive than anavar or winstrol, so unauthenticated halotestin is treated as presumptively fake, underdosed, or substituted. A user who cannot verify product identity, run labs, and stop when liver, lipid, blood-pressure, or behavior signals move the wrong way is outside the practical use case.
Risks & Monitoring
The hepatotoxicity risk is the central concern and determines the entire dosing framework. Fluoxymesterone is C17-alpha-alkylated (oral bioavailability mechanism), which burdens the liver with sustained first-pass exposure.
The dominant DILI pattern is bland cholestasis — intrahepatic cholestasis with elevated bilirubin and alkaline phosphatase; AST/ALT elevation is typically mild-to-moderate (2-5x ULN) at clinical doses.
The dose-duration matrix determines severity: hepatic enzyme elevations are minimal at doses 20 mg/day or less in the majority of users. Above 20 mg/day or beyond 4 weeks, risk escalates sharply. Three documented clinical cases of severe cholestatic jaundice occurred at doses 30-40 mg/day for 6-12 weeks — all resolved upon discontinuation within 2-4 months. One case of peliosis hepatis (blood-filled hepatic cysts) occurred at 20 mg/day for 2 years. Hepatocellular carcinoma cases come from women at 40-80 mg/day for over 24 months in palliative breast cancer treatment — not from athletic use patterns. Community experience corroborates this: a user who extended to 6 weeks at 15 mg hit 8x ULN liver enzymes and was clinically mistaken for alcoholic hepatitis.
Cardiovascular is the second major concern. HDL crashes are rapid and severe: one documented log showed HDL dropping from 54 to 18 mg/dL in 4 weeks at 20 mg/day; another dropped from 52 to 11 mg/dL in 3 weeks. Recovery occurs but takes 10-12 weeks. The 11-HSD2 inhibition mechanism also drives sodium retention and blood pressure elevation — one log recorded BP rising from 118/72 to 138/88 within 2 weeks.
CNS aggression is dose-dependent, rapid-onset (hours), and highly variable between individuals. Some users report minimal mood effects at 20 mg; others lose social control at 15 mg. The aggression is not gym-specific — it spills into daily life, damaging relationships and creating social liability. Community reports document grocery store altercations, relationship fractures, and workplace conflicts. Night sweats and sleep disruption from noradrenergic activation are consistent across logs.
HPG suppression is complete within 1-2 weeks at 10-20 mg/day. Because halotestin does not aromatize, estrogen levels also fall during the cycle — compounding the libido and mood depression beyond what testosterone suppression alone would produce. Libido cessation by week 3 is reported even when testosterone propionate is included as a base. Testicular atrophy occurs at 10 mg/day or more with use exceeding 4 weeks.
Hair loss is mechanistically unusual. Halotestin does not convert to DHT (the 11-beta-hydroxy group blocks A-ring reduction, making 5-alpha-reductase metabolism very inefficient). Fertility trials at 30 mg/day for 12 months documented zero hair loss progression. However, direct AR binding in hair follicles can still cause follicle miniaturization via a DHT-independent pathway in genetically prone individuals. Finasteride provides no protection. Community reports are therefore mixed — users with high DHT sensitivity may still experience significant loss; others may tolerate halotestin better than testosterone from a hair perspective.
Depression emerges post-cycle and during cycle in the absence of estrogen. The combination of HPG suppression, falling estrogen (no aromatization), and CNS noradrenergic dysregulation can produce prolonged post-cycle mood disturbance. One log described feeling emotionally flat for 3 months post-cycle despite testosterone recovering on schedule.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish pre-cycle hepatic baseline. Any pre-existing elevation is a contraindication. The C17-alkylated structure causes cholestatic DILI in a dose- and duration-dependent manner.
Check at week 2-3 of cycle. ALT above 3x ULN warrants dose reduction or immediate discontinuation. Community data shows ALT can reach 2-8x ULN within 3-4 weeks even at moderate doses.
Check at 4 weeks post-cycle and again at 8 weeks. Community data shows LFT normalization by 6-8 weeks for most short cycles; prolonged elevation signals ongoing hepatic stress.
Establish HDL baseline. HDL can crash to single digits within 3-4 weeks at 20-30 mg/day. Any baseline HDL below 40 mg/dL is a significant risk flag before starting.
Check at 6-8 weeks post-cycle. HDL recovery typically takes 10-12 weeks. Persistent suppression below 30 mg/dL warrants cardiovascular consultation.
11-HSD2 inhibition causes mineralocorticoid excess with sodium retention and BP elevation. BP has risen from 118/72 to 138/88 within 2 weeks in documented cases. BP above 140/90 should trigger dose reduction, clinician review, or an already planned antihypertensive response rather than simply pushing through the run.
Confirm HPG axis recovery. HPG suppression is complete within 1-2 weeks; natural T returns to baseline in 6-10 weeks after a 4-week cycle. Delayed recovery (>12 weeks) should trigger endocrinology referral.
Confirm gonadotropin recovery alongside testosterone. LH and FSH should begin recovering within 4-6 weeks post-cycle. Persistent suppression confirms ongoing HPG dysfunction and should guide recovery support with medical oversight.
Fluoxymesterone stimulates red blood cell production per FDA label. Elevated baseline hematocrit above 50% is a risk factor for additional erythrocytosis-driven cardiovascular risk during cycle.
Monitor erythrocytosis during cycle if baseline hematocrit was borderline. Exceeding 54% during cycle is a stop signal.
Avoid With
Do not combine Halotestin with the following. Sorted highest-severity first.
Why:Complete HPG suppression within 1-2 weeks with no exogenous testosterone replacement results in zero functional sex hormones. Halotestin provides androgenic stimulus but no androgenic support for sexual function. Libido crashes, erectile function fails within 2 weeks, and testicular atrophy progresses without any net anabolic benefit.
What to do:This is the single most common mistake documented in community threads. Always run testosterone propionate 100-200 mg/week as a base.
Why:The 9-alpha-fluoro GC-MS signature is structurally unique and cannot be masked. WADA detection window is up to 8 weeks after last dose. No masking agent, diuretic protocol, or timing adjustment can circumvent a properly conducted urine test.
What to do:Banned since the 1976 Montreal Olympics. Any tested athlete using this compound should expect a positive test if any sample is collected within 8 weeks of last dose.
Why:Additive hepatic burden. All 17-alpha-alkylated orals cause dose- and duration-dependent cholestatic hepatotoxicity. Combining two simultaneously multiplies the total daily hepatic load. If stacking (e.g., halo + winstrol for contest prep), total combined duration must be capped at 4 weeks and LFTs must be monitored mid-cycle.
What to do:The contest prep halo+winstrol stack is widely used but inherently higher-risk. Keep winstrol at 50 mg/day or less and total stack duration at 4 weeks maximum.
Why:Halotestin upregulates central norepinephrine via locus coeruleus. Combining with other sympathomimetic CNS stimulants can push noradrenergic activity to unsafe levels: hypertensive crisis, cardiac arrhythmia, or extreme aggression/psychosis risk.
What to do:Pre-workout stimulant stacks should be simplified or eliminated during halotestin use. Blood pressure monitoring is mandatory.
Why:Any agent with independent hepatotoxic potential adds to the C17-alkylated liver burden. The cholestatic DILI pattern of halotestin can be compounded by other hepatotoxic insults, increasing severity and reducing reversibility.
What to do:Review all prescription medications for hepatotoxic potential before running halotestin. NSAIDs at chronic doses also add hepatic burden.
Protocols By Goal
Powerlifting or strength peak. Reported use is a short competition-prep exposure intended to improve neural drive on meet day. Some users describe meaningful meet-day strength increases, but the liver, lipid, blood-pressure, aggression, and anti-doping burden is high.
Combat sports. Reports focus on aggression and finishing intent, but cardio impairment, judgment changes, and tested-sport risk make this an especially narrow and ethically fraught lane.
Contest-prep finisher. Some physique users use it briefly for hardening and training intensity, but it contributes little mass and can make mood/behavior visibly worse.
Not appropriate for. Women, beginners, off-season bulking, long recomposition blocks, users with liver/lipid/BP risk, volatile life circumstances, or any drug-tested context.
Dosing Details
Reported halotestin use is competition-specific, short, and high-burden. Community practice clusters around brief pre-event or final-prep exposure, usually in the 10-20 mg/day range, with higher exposures reserved for very short peak windows and treated as sharply riskier. The intended effect is CNS drive, aggression, neural output, and short-term strength expression, not new muscle accrual.
Male users generally pair it with a testosterone base because halotestin is suppressive and non-aromatizing. Recovery planning, liver enzymes, HDL, blood pressure, sleep, and behavior are part of the field protocol, but exact ancillary drug choices should be individualized rather than copied from bodybuilding shorthand.
A hard duration ceiling is central to observed practice: extended use is where liver, lipid, blood-pressure, and behavioral risk becomes disproportionate. Halotestin is not for off-season bulking, casual strength cycles, or general recomposition.
Stacks & Alternatives
Mandatory base. Halotestin causes complete HPG suppression within 1-2 weeks — without exogenous testosterone, the user has zero sex hormones. Test propionate 100-200 mg/week is standard. Short ester preferred for faster post-cycle clearance.
Classic contest prep finisher stack. Winstrol adds hardening and vascularity without water retention; halotestin adds CNS drive and anti-catabolic effect during deep caloric deficit. Both are 17-alpha-alkylated — combined liver burden requires strict duration limits (4 weeks max for the combination).
Liver support essential during any halotestin cycle. 500 mg/day throughout the cycle is community standard. TUDCA reduces cholestatic stress and supports bile flow, partially mitigating the C17-alkylated hepatic burden.
Common male recovery support after suppressive oral-AAS use. HPG suppression from even a 4-week cycle may require assisted recovery to avoid prolonged hypogonadism; dose and agent choice should be guided by labs and medical context.
Post-cycle liver support. 600 mg/day for 4-8 weeks post-cycle to support hepatic recovery. Complements TUDCA during the cycle, then continues after stopping when TUDCA is typically discontinued.
Advanced contest prep finisher combination. Community educator recommends the halo+superdrol stack specifically for contests. Both are highly hepatotoxic oral androgens — this combination is only defensible for a maximum 2-3 week contest peak, not a full cycle.
Alternatives
Stack Cost
Halotestin is a very-high-tax oral AAS that spends liver, lipid, blood-pressure, HPG, behavior, sourcing, and testing capacity for one narrow payoff: short-window competition aggression and neural drive.
The article requires LFT and lipid monitoring, documents HDL crashes into the teens or single digits, describes cholestatic DILI cases at higher dose/duration, and ties 11-HSD2 inhibition to blood-pressure elevation.
The article says complete HPG suppression can occur within 1-2 weeks at 10-20 mg/day and rejects oral-only cycles because halotestin does not provide aromatized estrogen support.
The practical upside is CNS aggression and drive, but the article repeatedly notes that aggression can spill into relationships, work, and daily life rather than staying confined to training.
WomenConsiderations labels virilization risk high, pregnancy contraindicated, and female performance use not recommended. Male fertility use is a separate historical clinical context, not a green light for athletic cycles.
The article describes halotestin as expensive and frequently faked because raw fluoxymesterone costs far more than common substitute orals.
- ·Do not treat halotestin as a mass-building slot; the article frames zero mass gain as the central community consensus.
- ·Keep total oral-AAS exposure tightly time-boxed because liver, lipid, and blood-pressure tax accumulate faster than the useful CNS window.
- ·A testosterone base and recovery plan are part of the capacity cost for male use; halotestin-only cycles spend suppression capacity without solving estrogen or libido support.
- ·Behavioral capacity matters as much as lab capacity: volatile relationships, anger issues, high-stress work, or poor sleep are practical contraindications in the article.
- ·Product verification is not optional for interpretation because fake or substituted halo can make both effects and side effects misleading.
- ·Baseline, mid-cycle, and post-cycle LFTs with bilirubin and ALP
- ·Baseline and post-cycle lipid panels, with HDL recovery confirmed before another oral cycle
- ·Blood-pressure tracking and a predefined stop/reduce threshold
- ·Male testosterone-base and post-cycle recovery planning
- ·Third-party product authentication before first use
The article has no beginner-friendly use case: complete suppression, harsh lipid and liver movement, behavioral volatility, sourcing fraud, WADA detection, and no mass-gain upside.
- ·The goal is bulking, recomposition, or ordinary gym strength
- ·The user lacks mid-cycle labs or blood-pressure tracking
- ·The user is female, pregnant, trying to conceive, or unwilling to accept virilization risk
- ·The user is drug-tested
- ·The user has anger-management problems, unstable relationships, or high-stress obligations during the run
Stopping the tablet is simple, but the article expects HDL recovery over 10-12 weeks, LFT follow-up at 4 and 8 weeks, possible 6-10 week testosterone recovery after short cycles, and potentially longer behavioral or mood fallout.
- ·HDL remains suppressed after subjective side effects fade
- ·LFTs or bilirubin remain elevated
- ·Low-libido and low-mood symptoms after suppression
- ·Relationship or work damage from aggression during the run
- ·Confusion when fake product produced unexpected effects
Anchor the run to a dated event, cap duration, and stop if the goal shifts from acute neural drive to body-composition change.
Reduce or stop early. The article treats social spillover as a core risk, not a tolerable nuisance.
Run the required labs and stop for jaundice, major LFT elevation, severe BP elevation, or HDL collapse.
Verify product identity before interpreting dose response or escalating.
Small red flags matter because the useful window is short and the downside can be severe. Jaundice, ALT above 3x ULN, BP above 160/100, uncontrolled aggression, or signs of female virilization should override the planned protocol.
Practical Setup
Halotestin is one of the least forgiving oral AAS. The practical gates are liver enzymes, HDL/LDL, blood pressure, sleep, aggression/impulsivity, and tested-sport status.
If ALT/AST rise sharply, jaundice or right-upper-quadrant pain appears, blood pressure becomes severe, or behavior becomes hard to control, the risk-benefit case collapses.
Product-identity risk is high because substituted or underdosed oral steroids are common in this category. Public guidance should stay generic: identity confirmation and clear labeling matter; named testing services, access-route details, and price-chasing do not belong in reader-facing prose.
Women should not use halotestin for performance or physique goals. The article preserves historical and clinical observations because they are informative, but the conclusion is bluntly not recommended: virilization, voice change, clitoral enlargement, hairline changes, menstrual disruption, and endocrine suppression can occur, and some changes may be irreversible.
Mechanism Deep Dive
Androgen receptor binding and the anabolic paradox
Fluoxymesterone binds the androgen receptor with approximately 19x the affinity of testosterone (Kd ~0.3 nM; 1900% relative binding affinity). The anabolic-to-androgenic ratio by receptor binding assay is 1900/1600 — suggesting a compound with strong anabolic potential. In clinical practice, that anabolic potential does not materialize. Two in-vivo inactivation mechanisms explain the dissociation:
1. 11-beta-hydroxy oxidation: In peripheral tissues, the 11-beta-hydroxy group is oxidized to an 11-keto group, producing 11-keto-fluoxymesterone. This metabolite has dramatically reduced AR affinity. Because this conversion happens in metabolically active peripheral tissues including muscle, the active androgenic molecule is inactivated before it can drive sustained protein synthesis.
2. A-ring reduction by 9-alpha-fluoro group: The 9-alpha-fluoro group, which increases receptor binding in vitro, also promotes rapid A-ring reduction to less-active metabolites specifically in muscle tissue. The net effect: in CNS and androgenic tissues (where the oxidation/reduction pathways are less active), the full androgenic potency is preserved. In skeletal muscle, the compound is rapidly inactivated.
This profile distinguishes halotestin from oxymetholone and oxandrolone, which retain their anabolic activity in vivo. Halotestin is neurologically and androgenically potent; anabolically, it is weak.
CNS noradrenergic aggression mechanism
The aggression and neural drive effect is mediated through central noradrenergic pathways, distinct from AR-to-anabolic signaling. Rodent studies show fluoxymesterone upregulates norepinephrine synthesis in the locus coeruleus — the brainstem nucleus that is the primary source of noradrenergic projection to the forebrain. This upregulation drives downstream sympathetic activation and lowers the aggressive behavior threshold. The effect is dose-response rapid (onset hours, not weeks) and does not require sustained AR occupation for protein synthesis.
Fluoxymesterone also binds glucocorticoid receptors with moderate affinity. At CNS sites, GR activation contributes to altered stress response and further lowers the aggression threshold. At skeletal muscle, partial GR agonism may provide mild anti-catabolic protection — a plausible explanation for the hardening quality observed during caloric deficit use.
11-beta-HSD2 inhibition and the mineralocorticoid excess mechanism
The 11-beta-hydroxy group acts as a competitive inhibitor of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) with IC50 approximately 60-100 nM in human renal microsomes. This IC50 is clinically relevant at doses of 10-20 mg/day. 11beta-HSD2 normally oxidizes cortisol to the inactive cortisone in mineralocorticoid-sensitive tissues (kidney tubules, colon, salivary glands). By blocking this inactivation, halotestin allows cortisol to accumulate at mineralocorticoid receptors — producing apparent mineralocorticoid excess syndrome: sodium retention, potassium loss, and blood pressure elevation. This also suppresses endogenous aldosterone via feedback (cortisol occupying the receptor mimics high aldosterone signaling), which is the mechanistic basis for the weight-cut benefit in combat sports.
Non-aromatization and the estrogen deficit
Halotestin does not aromatize to estradiol. While this eliminates gynecomastia and estrogen-driven water retention, it also means that HPG suppression (which eliminates endogenous testosterone) is not compensated by any estrogen production from aromatization of exogenous androgenic activity. Estrogen levels fall during a halotestin cycle, compounding the libido and mood depression beyond what testosterone suppression alone would produce. This is mechanistically distinct from aromatizing androgens where estrogen partially buffers the HPG suppression effects.
DHT conversion and the hair loss non-mechanism
Halotestin does not convert to dihydrotestosterone via 5-alpha-reductase. The 11-beta-hydroxy group blocks A-ring reduction, making the 5-alpha-reductase pathway very inefficient for fluoxymesterone. The primary hair loss mechanism for most AAS (DHT elevation in androgen-sensitive follicles) is bypassed. Fertility trials at 30 mg/day for 12 months documented zero scalp hair progression. However, direct AR binding in androgen-sensitive hair follicles can still drive follicle miniaturization via a DHT-independent route in genetically susceptible individuals — explaining why community reports of hair loss still exist despite the fertility trial data. Finasteride provides no protection because there is no DHT to block.
Hepatotoxicity mechanism
The 17-alpha-alkylation that provides oral bioavailability (~80%) is the structural basis for hepatotoxicity. The 17-alpha-methyl group blocks the hepatic first-pass oxidation that would otherwise inactivate the compound. This means a higher steady-state drug concentration reaches systemic circulation, but also that the liver is exposed to a sustained, relatively undepleted concentration of a potent androgenic molecule with each pass. The dominant DILI pattern is cholestasis: impaired bile flow with bilirubin and alkaline phosphatase elevation. AST/ALT elevation is typically mild-to-moderate (2-5x ULN) at clinical doses. At higher doses or longer durations, peliosis hepatis (blood-filled hepatic cysts) and, in extreme cases of prolonged high-dose use, hepatocellular carcinoma have been documented.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
A documented powerlifting log reported a 55 kg competition-day total increase while using 20 mg/day for 4 weeks with a testosterone propionate base.
Useful for the meet-day CNS niche, but it should not be generalized to ordinary strength cycles or mass-building outcomes.
Users report about 2-3 lb of water loss in the week before weigh-in, tied to the 11-HSD2/mineralocorticoid mechanism.
Relevant to weigh-in strategy only; BP and potassium monitoring still matter because the same mechanism can create mineralocorticoid-excess problems.
A review of 17 clinical trials for male subfertility found improved fertility parameters at 10-30 mg/day for 3-12 months despite LH/FSH suppression.
The article treats this as a paradoxical clinical context; it should not soften the athletic-cycle suppression warning.
Severe cholestatic jaundice cases occurred at 30-40 mg/day for 6-12 weeks and resolved after discontinuation over 2-4 months.
Supports strict duration and dose boundaries; case reports show plausible severity but not incidence.
HDL has dropped from 54 to 18 mg/dL in 4 weeks at 20 mg/day and from 52 to 11 mg/dL in 3 weeks in documented logs.
Practical lipid-risk signal, not controlled incidence data. The article uses it to justify required lipid monitoring.
One community member extended to 6 weeks at 15 mg/day and developed 8x ULN liver enzymes.
Supports the article duration cap but should be read as a warning case, not expected response for all users.
Historical female clinical and doping contexts report menstrual disruption, amenorrhea, and virilization at athletic or palliative doses.
Supports the article recommendation against female performance use and the high virilization-risk label.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.